Search

Xianzhi J Mao

from Washington Crossing, PA
Age ~62
Get Report
Also known as:
Xianzhi Z Mao, Xingzhi Mao, Mao Xianzhi, Mao Etal Xianzhi, I Mao
Related to:
Jack Z MaoEvan Z Mao, 30Lingjuan Tang, 61
Connected to:
Angela F Mao, 38Baodong Mao, 42Calvin K Mao, 34Carolyn Mao, 33Cathy S Mao, 40Changshi Mao, 59Chengde Mao, 60Cody V Mao, 28Cui L Mao, 67Cuiping Mao, 38

Xianzhi Mao Phones & Addresses

  • Washington Crossing, PA
  • 2101 Seneca Run, Ambler, PA 19002 (215) 542-0752
  • 6147 Oakley St, Philadelphia, PA 19111
  • 310 Crimson Ct, Warrington, PA 18976 (215) 491-1535
  • 108 Park Ave, Jenkintown, PA 19046
  • 2101 Seneca Run, Ambler, PA 19002 (215) 416-6839

Work

Position: Protective Service Occupations

Education

Degree: Associate degree or higher

Publications

Us Patents

Human Receptor Tyrosine Kinase, Kdr

View page
US Patent:
6359115, Mar 19, 2002
Filed:
Jan 14, 2000
Appl. No.:
09/483539
Inventors:
Richard L. Kendall - Doylestown PA
Xianzhi Mao - Rockledge PA
Kenneth A. Thomas - Chatham Borough NJ
Andrew Tebben - Harleysville PA
Assignee:
Merck Co., Inc. - Rahway NJ
International Classification:
C07K 1471
US Classification:
530350, 530402, 435 694
Abstract:
An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.

Human Receptor Tyrosine Kinase, Kdr

View page
US Patent:
6841367, Jan 11, 2005
Filed:
Mar 18, 2002
Appl. No.:
10/100405
Inventors:
Richard L. Kendall - Doylestown PA, US
Kenneth A. Thomas - Chatham Borough NJ, US
Xianzhi Mao - Rockledge PA, US
Andrew Tebben - Harleysville PA, US
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C07K 1471
C12Q 125
US Classification:
435183, 435 691, 435 71, 435 78, 530350, 536 232, 536 234, 536 235
Abstract:
An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.

Human Receptor Tyrosine Kinase, Kdr

View page
US Patent:
6841382, Jan 11, 2005
Filed:
Dec 18, 2001
Appl. No.:
10/022939
Inventors:
Richard L. Kendall - Doylestown PA, US
Kenneth A. Thomas - Chatham Borough NJ, US
Xianzhi Mao - Rockledge PA, US
Andrew Tebben - Harleysville PA, US
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C12N 510
C07K 1471
US Classification:
435325, 435 691, 435 697, 435183, 4352523, 43525411, 530350, 536 235, 536 234
Abstract:
An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.

In Vivo Methods Of Determining Activity Of Receptor-Type Kinase Inhibitors

View page
US Patent:
20040101478, May 27, 2004
Filed:
Sep 29, 2003
Appl. No.:
10/473513
Inventors:
Kenneth Thomas - Chatham Borough NJ, US
Xianzhi Mao - Ambler PA, US
Richard Kendall - Thousand Oaks CA, US
International Classification:
A61K049/00
G01N033/567
US Classification:
424/009200, 435/007210
Abstract:
In vivo methods are disclosed for measuring compound inhibition of kinase receptor activity. Examples are provided which show a direct correlation between in vivo inhibition of KDR kinase inhibition and circulating blood and plasma levels of the inhibitor. These data are used to predict and validate non-quantifable in vitro measurements, such as murine endothelial cell ICvalues. The in vivo potency of a compound determined by an assay of the present invention may be utilized to select dose amounts and frequencies for further preclinical animal model studies and human clinical studies designed to generate safety, potency and efficacy profiles for the respective inhibitor.

Human Receptor Tyrosine Kinase, Kdr

View page
US Patent:
62040111, Mar 20, 2001
Filed:
Jun 17, 1998
Appl. No.:
9/098707
Inventors:
Richard L. Kendall - Doylestown PA
Xianzhi Mao - Rockledge PA
Kenneth A. Thomas - Chatham Borough NJ
Andrew Tebben - Harleysville PA
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C12N 1512
US Classification:
435 691
Abstract:
An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.

Compositions For Inhibiting Checkpoint Gene Expression And Uses Thereof

View page
US Patent:
20180044669, Feb 15, 2018
Filed:
Oct 26, 2017
Appl. No.:
15/794643
Inventors:
- Cambridge MA, US
Wayne JIANG - Waltham MA, US
Daqing Wang - Bedford MA, US
Jessica Seitzer - Windham NH, US
Xianzhi Mao - Ambler PA, US
International Classification:
C12N 15/11
A61K 31/7105
C12N 15/113
A61K 45/06
Abstract:
The present invention is directed to compounds, compositions, and methods useful for modulating PD1, PDL1, IDO1, LAG3, TIM3, CTLA4, IDO2, CEACAM1, OX40, and/or OX40L mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5′-ends to allow the presence of two or more accessible 3′-ends.

Compositions For Inhibiting Checkpoint Gene Expression And Uses Thereof

View page
US Patent:
20160251652, Sep 1, 2016
Filed:
Feb 25, 2016
Appl. No.:
15/053309
Inventors:
- Cambridge MA, US
Wayne Jiang - Waltham MA, US
Daqing Wang - Bedford MA, US
Jessica Seitzer - Windham NH, US
Xianzhi Mao - Ambler PA, US
International Classification:
C12N 15/11
A61K 45/06
A61K 31/7105
Abstract:
The present invention is directed to compounds, compositions, and methods useful for modulating PD1, PDL1, IDO1, LAG3, TIM3, CTLA4, IDO2, CEACAM1, OX40, and/or OX40L mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5′-ends to allow the presence of two or more accessible 3′-ends.
Control profile
Xianzhi J Mao from Washington Crossing, PA, age ~62 Get Report